SOURCE: The Bedford Report

The Bedford Report

January 03, 2011 08:46 ET

Biotech Sector Poised for Growth in 2011

The Bedford Report Provides Analyst Research on Cell Therapeutics & Aastrom Biosciences

NEW YORK, NY--(Marketwire - January 3, 2011) - Biotech companies have not been impervious to the economic downturn, but they have endured better than most. This is due in part to the fact that demand for pharmaceuticals remains fairly constant even during recession. As 2011 kicks off there is plenty of optimism regarding the Biotech Industry as firmer pricing and new products have improved sales and earnings trends. Moreover -- similar to last year -- Merger & Acquisition activity is likely to play a large part throughout the sector. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Access to the full company reports can be found at:

www.bedfordreport.com/2011-01-CTIC

www.bedfordreport.com/2011-01-ASTM

The healthcare industry research firm IMS Health projects an increase in worldwide growth in 2011. The firm forecasts 5% to 7% versus a pace of 4% to 5% in 2010. The firm has a meager growth outlook until at least 2015. 

Much of the growth is expected to come from emerging markets such as China, Brazil, India and South Korea. These countries are benefiting from increased government spending on health care and more extensive private health coverage for workers. IMS predicts sales growth of 15% in these markets.

The Bedford Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

In recent Biotech news, Cell Therapeutics announced that it has filed an appeal of FDA's decision regarding the company's "pixantrone" drug for non-Hodgkin's lymphoma. Back in April the FDA recommended that cell Therapeutics conduct another trial of pixantrone "to demonstrate the safety and effectiveness of its product."

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: http://www.bedfordreport.com/disclaimer.php.

Contact Information